Actualités et événements

Actualités

Communiqués de presse

Tous les communiqués de presse

Conférences

31 Mai - 4 Juin 2019 | McCormick Place, Chicago IL, USA

ASCO 2019

Du 31 Mai au 4 Juin, Median participe à la réunion annuelle de l’ASCO qui se tiendra à Chicago. Nous serons heureux de vous retrouver sur notre stand 6102 autour de nos solutions et services pour l’analyse et la gestion des images dans les essais cliniques en oncologie et de notre plateforme d’imagerie phénomique iBiopsy®.

Voir le site de la conférence
Toutes les conférences

Dans La Presse

iBiopsy® for Precision Medicine

Notre article sur iBiopsy® a été publié dans the European Medical Journal daté du 13 Décembre 2018 -> http://viewer.zmags.com/publication/647c38a3#/647c38a3/50

Abstract

A high-throughput artificial intelligence-powered image-based phenotyping platform, iBiopsy® (Median Technologies, Valbonne, France), which aims to improve precision medicine, is discussed in the presented review. The article introduces novel concepts, including high-throughput, fully automated imaging biomarker extraction; unsupervised predictive learning; large-scale content-based image-based similarity search; the use of large-scale clinical data registries; and cloud-based big data analytics to the problems of disease subtyping and treatment planning. Unlike electronic health record-based approaches, which lack the detailed radiological, pathological, genomic, and molecular data necessary for accurate prediction, iBiopsy® generates unique signatures as fingerprints of disease and tumor subtypes from target images. These signatures are then merged with any additional omics data and matched against a large-scale reference registry of deeply phenotyped patients. Initial applications targeted include hepatocellular carcinoma and other chronic liver diseases, such as nonalcoholic steatohepatitis. This new disruptive technology is expected to lead to the identification of appropriate therapies targeting specific molecular pathways involved in the detected phenotypes to bring personalised treatment to patients, taking into account individual biological variability, which is the principal aim of precision medicine.

See all in the press

Blog

Tous les posts sur notre blog

Cookies help us deliver our services. By using our services, you agree to our use of cookies.